You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
潛力 | 恒指季調14日市後重磅揭曉,哪些個股有望被納入?

本週五(14日)市後,恒指將迎來季度調整,其中阿里巴巴、美團點評、藥明生物等股票呼聲較高。

阿里巴巴早市升超1%,美團點評微升0.3%,藥明生物升6%。

中金公司稱,初步測算阿里巴巴、美團點評、安踏體育、阿里健康、藥明生物、華潤啤酒排在恒生指數選擇順位前列。如果上述公司能夠被納入恒生指數,料分別對應7.6億美元、9.9億美元、2.6億美元、3.2億美元、2.8億美元和2.2 億美元的潛在被動資金流入。

排在順位靠後的股票為中國神華、太古、信和置業、恒隆地產、中國旺旺、新世界發展,若被剔除的話,將引發4800萬到1.5億美元不等的資金流出。

目前金融板塊在恒生和國企指數中佔比分別高達約48%和41%,如果互聯網龍頭公司如阿里巴巴和美團能夠順利納入的話,有望明顯提升新經濟板塊在指數中的佔比。

中泰證券稱,考慮阿里於電商及美團於線上消費所在行業的代表性,相信有較大機會被納入恒指。由於瑞聲科技)及舜宇光學等兩隻手機設備股已是藍籌,因此小米的機會率相對較小。然而,在樂觀情境下,若三間公司於此次季檢同時被納入,估計權重佔比將共計達到11.4%。預計美團、阿里及小米將共吸引22.5億美元被動資金配置。藥明生物有機會取代石藥成為藍籌股。

預計太古A、信置、長江基建、恒隆地產、中信股份有機會被剔出恒指。

對於恒指新貴後續股價走勢,中泰證券指出,潛在被納入恒指的股份有機會在恒指公司宣佈季檢結果後短線上升,但利好將很快被市場消化,被正式納入恒指當日可能不會僅因被動資金買入而上升,未來股價發展仍需關注基本面變化

本次恒指系列指數調整將於8月14日收市宣佈,97日指數調整生效,投資者可積極關注相關個股投資機會。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account